SCYX vs. VXRT, ACRV, CDTX, ALEC, ACRS, IKT, GLSI, IPHA, FATE, and CKPT
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Vaxart (VXRT), Acrivon Therapeutics (ACRV), Cidara Therapeutics (CDTX), Alector (ALEC), Aclaris Therapeutics (ACRS), Inhibikase Therapeutics (IKT), Greenwich LifeSciences (GLSI), Innate Pharma (IPHA), Fate Therapeutics (FATE), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical products" industry.
SCYNEXIS vs.
SCYNEXIS (NASDAQ:SCYX) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.
In the previous week, SCYNEXIS's average media sentiment score of 0.00 equaled Vaxart'saverage media sentiment score.
SCYNEXIS received 195 more outperform votes than Vaxart when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 65.54% of users gave Vaxart an outperform vote.
SCYNEXIS has higher revenue and earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
SCYNEXIS has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
SCYNEXIS has a net margin of -425.41% compared to Vaxart's net margin of -431.61%. SCYNEXIS's return on equity of -66.21% beat Vaxart's return on equity.
Vaxart has a consensus price target of $4.00, indicating a potential upside of 460.62%. Given Vaxart's higher probable upside, analysts clearly believe Vaxart is more favorable than SCYNEXIS.
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 18.1% of Vaxart shares are held by institutional investors. 2.9% of SCYNEXIS shares are held by company insiders. Comparatively, 2.6% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
SCYNEXIS beats Vaxart on 11 of the 14 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
This page (NASDAQ:SCYX) was last updated on 2/22/2025 by MarketBeat.com Staff
